Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1985 2
1986 3
1987 3
1988 3
1990 2
1991 3
1992 3
1993 4
1994 1
1996 6
1997 3
1998 5
1999 2
2000 9
2001 9
2002 7
2003 6
2004 7
2005 4
2006 7
2007 7
2008 11
2009 8
2010 13
2011 19
2012 19
2013 19
2014 28
2015 19
2016 29
2017 35
2018 33
2019 34
2020 26
2021 36
2022 29
2023 25
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Results by year

Filters applied: . Clear all
Page 1
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Iyer SP, et al. Among authors: horwitz sm. Lancet Oncol. 2024 Nov 28:S1470-2045(24)00508-4. doi: 10.1016/S1470-2045(24)00508-4. Online ahead of print. Lancet Oncol. 2024. PMID: 39617017
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA. Horwitz SM, et al. Nat Med. 2024 Nov 15. doi: 10.1038/s41591-024-03404-w. Online ahead of print. Nat Med. 2024. PMID: 39548313 No abstract available.
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg AR, Disciullo A, Chopra K, Lenart AW, Nwodo E, Barnes JA, Koh MJ, Miranda ECM, Chiattone CS, Stuver RN, Horwitz SM, Merrill MH, Jacobsen ED, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim YR, Kim JS, Cho JY, Eipe T, Shet T Dr, Epari S, Shetty A, Saha S, Jain H Dr, Sengar M MD, DM, Van Der Weyden C, Prince HM, Hamouche R, Muradashvili T, Foss FM, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Han JX, et al. Among authors: horwitz sm. Blood Adv. 2024 Oct 31:bloodadvances.2024014674. doi: 10.1182/bloodadvances.2024014674. Online ahead of print. Blood Adv. 2024. PMID: 39481087
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Zinzani PL, et al. Among authors: horwitz sm. Lancet Oncol. 2024 Oct 29:S1470-2045(24)00503-5. doi: 10.1016/S1470-2045(24)00503-5. Online ahead of print. Lancet Oncol. 2024. PMID: 39486433
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM. Maruyama D, et al. Among authors: horwitz sm. Lancet Oncol. 2024 Oct 29:S1470-2045(24)00502-3. doi: 10.1016/S1470-2045(24)00502-3. Online ahead of print. Lancet Oncol. 2024. PMID: 39486432
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
Lue JK, Luttwak E, Rivas-Delgado A, Irawan H, Boardman A, Caron PC, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Palomba ML, Steiner R, Stuver R, Torka P, Vardhana S, Zelenetz AD, Schoder H, Imber B, Yahalom J, Zhang Y, Galera P, Dogan A, Aypar U, Salles G. Lue JK, et al. Among authors: horwitz sm. Blood Cancer J. 2024 Oct 14;14(1):178. doi: 10.1038/s41408-024-01148-x. Blood Cancer J. 2024. PMID: 39402034 Free PMC article. No abstract available.
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron PC, Epstein-Peterson Z, Ghione P, Hamlin P, Lue J, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Moskowitz A, Noy A, Owens C, Palomba LM, Torka P, Galera P, Zelenetz AD, Salles G, Falchi L. Cassanello G, et al. Among authors: horwitz sm. Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600. Online ahead of print. Haematologica. 2024. PMID: 39234863 Free article.
A Novel JAK2 Fusion in T-Cell Prolymphocytic Leukemia.
Eren OC, Stuver R, Zhou T, Zaidinski M, Moskowitz AJ, Horwitz SM, Ewalt MD, Zhang Y, Lim MS. Eren OC, et al. Among authors: horwitz sm. Genes Chromosomes Cancer. 2024 Jun;63(6):e23252. doi: 10.1002/gcc.23252. Genes Chromosomes Cancer. 2024. PMID: 39133763
444 results